ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

10 Fibro-Friendly Foods with a Bonus: Beautiful Skin

Studies Show that Magnesium L-threonate Improves Brain Plasticity, Leading to Direct and Significant...

Clary Sage Oil May Be Pricey, but Its Benefits Are Priceless

Pumpkin Pie Turmeric Breakfast Smoothie - Vegan + Gluten-Free

Component of red wine, grapes can help to reduce inflammation, study finds

Poly MVA: A Novel Therapy for Increasing Energy, Repairing DNA, and Promoting Overall Health

Vitamin D supplementation extends life in mouse model of Huntington's disease

Omega-3 fatty acid stops known trigger of lupus

Conquer Your Email Inbox, Increase Productivity and Reduce Stress

The Significance of Selenium

Print Page
Email Article

Cancer Breakthrough: Genetically weaponized T cells kill leukemia, provide ‘road map’ for attacking other cancers

  [ 57 votes ]   [ 2 Comments ] • August 10, 2011

Each genetically altered T cell killed a pound of tumor and created new ‘armies’ of reinforcements; remission persists.

In a cancer treatment breakthrough 20 years in the making, researchers from the University of Pennsylvania's Abramson Cancer Center and Perelman School of Medicine have shown sustained remissions of up to a year among a small group of advanced chronic lymphocytic leukemia (CLL) patients treated with genetically engineered versions of their own T cells.

The protocol, which involves removing patients' cells and modifying them in Penn's vaccine production facility, then infusing the new cells back into the patient's body following chemotherapy, provides a tumor-attack roadmap for the treatment of other cancers including those of the lung and ovaries and myeloma and melanoma.

The findings, published simultaneously Aug 10 by the New England Journal of Medicine [read the full report - “Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia” – HERE] and Science Translational Medicine, are the first demonstration of the use of gene transfer therapy to create "serial killer" T cells aimed at cancerous tumors.

"Within three weeks, the tumors had been blown away, in a way that was much more violent than we ever expected," says senior author Carl H June, MD.

"It worked much better than we thought it would," adds Dr. June, who directs translational research at the U of Pennsylvania’s Abramson Cancer Center.

The results of the pilot trial of three patients are a stark contrast to existing therapies for CLL.

The patients involved in the new study had few other treatment options. The only potential curative therapy would have involved a bone marrow transplant, a procedure which requires a lengthy hospitalization and carries at least a 20% mortality risk - and even then offers only about a 50% chance of a cure, at best.

"Most of what I do is treat patients with no other options, with a very, very risky therapy with the intent to cure them," says co-principal investigator David Porter, MD, professor of Medicine and director of Blood and Marrow Transplantation at U Penn.

"This approach has the potential to do the same thing, but in a safer manner."

Secret Ingredients

Dr. June thinks there were several "secret ingredients" that made the difference between the lackluster results that have been seen in previous trials with modified T cells and the remarkable responses seen in the current trial. The details of the new cancer immunotherapy are detailed in Science Translational Medicine.

• After removing the patients' cells, the team reprogrammed them to attack tumor cells by genetically modifying them using a lentivirus vector.

• The vector encodes an antibody-like protein, called a chimeric antigen receptor (CAR), which is expressed on the surface of the T cells and designed to bind to a protein called CD19.

• Once the T cells start expressing the CAR, they focus all of their killing activity on cells that express CD19, which includes CLL tumor cells and normal B cells.

• All of the other cells in the patient that do not express CD19 are ignored by the modified T cells, which limits side effects typically experienced during standard therapies.

Multiply Until Job is Done

The team engineered a signaling molecule into the part of the CAR that resides inside the cell. When it binds to CD19, initiating the cancer-cell death, it also tells the cell to produce cytokines that trigger other T cells to multiply - building a bigger and bigger army until all the target cells in the tumor are destroyed.

"We saw at least a 1000-fold increase in the number of modified T cells in each of the patients. Drugs don't do that," Dr. June says.
Serial Killers

"In addition to an extensive capacity for self-replication, the infused T cells are serial killers,” says Dr. June. “On average, each infused T cell led to the killing of thousands of tumor cells – and overall, destroyed at least two pounds of tumor in each patient."

The importance of the T cell self-replication is illustrated in the New England Journal of Medicine paper, which describes the response of one patient, a 64-year old man.

Prior to his T cell treatment, his blood and marrow were replete with tumor cells.

• For the first two weeks after treatment, nothing seemed to change.

• Then on day 14, the patient began experiencing chills, nausea, and increasing fever, among other symptoms.

• Tests during that time showed an enormous increase in the number of T cells in his blood that led to a tumor lysis syndrome, which occurs when a large number of cancer cells die all at once.

By day 28, the patient had recovered from the tumor lysis syndrome - and his blood and marrow showed no evidence of leukemia.

"This massive killing of tumor is a direct proof of principle of the concept," Dr. Porter says.

Safety Demonstrated

The Penn team pioneered the use of the HIV-derived vector in a clinical trial in 2003 in which they treated HIV patients with an antisense version of the virus. That trial demonstrated the safety of the lentiviral vector used in the present work.

Hopes for Protection Against Recurrence

The cell culture methods used in this trial reawaken T cells that have been suppressed by the leukemia and stimulate the generation of so-called "memory" T cells, which the team hopes will provide ongoing protection against recurrence.

Although long-term viability of the treatment is unknown, the doctors have found evidence that months after infusion, the new cells had multiplied and were capable of continuing their seek-and-destroy mission against cancerous cells throughout the patients' bodies.

Tests for Other Cancer Types in the Works

Moving forward:

• The team plans to test the same CD19 CAR construct in patients with other types of CD19-positive tumors, including non-Hodgkin's lymphoma and acute lymphocytic leukemia.

• They also plan to study the approach in pediatric leukemia patients who have failed standard therapy.

• Additionally, the team has engineered a CAR vector that binds to mesothelin, a protein expressed on the surface of mesothelioma cancer cells, as well as on ovarian and pancreatic cancer cells.

Source: University of Pennsylvania School of Medicine news release, Aug 10, 2011

Post a Comment

Featured Products From the ProHealth Store
Vitamin D3 Extreme™ FibroSleep™ Ultra ATP+, Double Strength

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments Post a Comment

cancer breakthrough
Posted by: kennet
Aug 11, 2011
i'm afraid to hope to much , like the liberration treatment for m s (my daughter has) it seems to have fallen by the wayside , my son has cancer , i pray this will leed to something good, we so much need to hear "WE FOUND IT', crying seems to be a way of life for me now, life would be wonderful for so many of us who's family is touched by this demon cancer!
Reply Reply

Sorry to hear about your kids.
Posted by: rocketzandco
Aug 31, 2011
I hope for the best.


Natural Pain Relief Supplements

Featured Products

Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

Improve Cardiovascular and Metabolic Health with Omega-7 Improve Cardiovascular and Metabolic Health with Omega-7
The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health
Aching Muscles? Top 10 Nutrients to Take Back Your Life Aching Muscles? Top 10 Nutrients to Take Back Your Life
Olea25 Olive Hydroxytyrosol Hits Astonishing 68,000+ ORAC Antioxidant Value Olea25 Olive Hydroxytyrosol Hits Astonishing 68,000+ ORAC Antioxidant Value
Red Yeast Rice - Natural Option for Supporting Healthy Cholesterol Red Yeast Rice - Natural Option for Supporting Healthy Cholesterol

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map